Please use this identifier to cite or link to this item:
|Title:||Cardiac effects of antimalarial treatment with halofantrine|
F. O. ter Kuile
N. J. White
D. E. Kyle
Shoklo Malaria Research Unit
Academic Medical Centre, University of Amsterdam
Armed Forces Research Institute of Medical Sciences, Thailand
John Radcliffe Hospital
|Citation:||The Lancet. Vol.341, No.8852 (1993), 1054-1056|
|Abstract:||In a prospective electrocardiographic study of Karen patients with acute uncomplicated falciparum malaria, mefloquine (25 mg/kg) had no cardiac effects (n=53), but halofantrine (72 mg/kg) induced consistent dose-related lengthening of the PR and QT intervals in all 61 patients treated. The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0·55 s1/2or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2·0 [95% Cl 1·1-3·4], p = 0·04). More than 60% of the effect occurred with three doses of halofantrine (24 mg/kg). The arrhythmogenic potential of halofantrine should now be investigated. © 1993.|
|Appears in Collections:||Scopus 1991-2000|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.